However, doubts still abound, researchers sought to assess whether markers such as CD10, CD133, nestin and CD20 could assess the prognosis of advanced melanoma, the results showed that they were unable to detect a significant correlation between nestin or CD133 expression in melanoma and patient survival or clinical outcome (35), which implies that CD133 may not exert a significant influence as a prognostic factor. This evidence concerns the gene NES and melanoma.